Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 P706 | DOI: 10.1530/endoabs.110.P706

1Vall d’Hebron Research Institute, Diabetes and Metabolism, Barcelona, Spain; 2Vall d’Hebron University Hospital, Human Pathology, Barcelona, Spain


JOINT352

Sex hormone-binding globulin (SHBG) plasma levels are reduced in subjects suffering MASLD and MASH. We have previously shown both In vitro and in vivo, that SHBG protects against MASLD development by reducing hepatic fat accumulation via inhibiting hepatic lipogenesis. In the present work, we are interested in exploring if SHBG could protect also against development of liver fibrosis. For this purpose, in vivo studies were performed using wild-type and the human SHBG transgenic mice developing liver fibrosis induced by carbon tetrachloride (CCl4). Our results clearly showed that SHBG overexpression reduced the CCl4 induced liver fibrosis in both male and female mice. Histological examination showed that SHBG transgenic mice had reduced NAS score and reduced collagen accumulation. Human SHBG transgenic mice treated with CCl4 had reduced Col1A1 mRNA and protein levels when compared with wild-type CCl4 treated mice. Mechanistically, we found that SHBG transgenic mice showed increased hepatic protein levels of several metalloproteases when compared with wild-type CCl4 treated mice. Taking together, we found for the first time that SHBG could protect against liver fibrosis by inhibiting Col1A1 mRNA and protein levels and by reducing collagen through an increase in MMPs activity.

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches